Subsequent prioritization revealed thioredoxin (TXN) as a candidate showing significant differential expression between multiple myeloma (MM) patients and controls, with elevated TXN levels observed in MM specimens (Supplemental Table 3). This evidence concerns the gene TXN and plasma cell myeloma.